Global Intensity-Modulated Radiotherapy Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 - 2032

Global Intensity-Modulated Radiotherapy Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 - 2032

Global Intensity-Modulated Radiotherapy Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 – 2032

Global Intensity-Modulated Radiotherapy Market was valued US$ 2.1 billion in 2022 and is expected to reach ~US$ 2.8 billion by 2032, growing at a CAGR of 5.8% during the forecast period 2023-2032.

Using computer-controlled linear accelerators, intensity-modulated radiation treatment (IMRT) is a sophisticated and extremely accurate form of radiotherapy that delivers precise doses of radiation to malignant tumours or particular areas within the tumour. By modifying, or regulating, the radiation beam's intensity over a number of tiny volumes, IMRT is able to attain this level of precision. This method minimises exposure to surrounding healthy tissues and important structures while enabling stronger radiation doses to be focused at the cancer in a way that closely matches its three-dimensional (3-D) shape.

In order to identify the best dose intensity pattern that follows the contours of the tumour, treatment planning entails using 3-D computed tomography (CT) or magnetic resonance imaging (MRI) scans of the patient in conjunction with computer-based dosage calculations. To provide a customised radiation dose that maximises tumour treatment while minimising radiation exposure to nearby normal tissues, a combination of numerous intensity-modulated fields emanating from different beam angles is typically used.

The Modulated Intensity Radiotherapy The growing prevalence of infections brought on by drug-resistant pathogens, improvements in diagnostic technologies, growing concern over antimicrobial resistance, government initiatives to combat antimicrobial-resistant species, and the emergence of multi-drug resistance as a result of substance abuse are some of the factors driving market expansion. On the other hand, the market's expansion is being limited by the high costs of antimicrobial resistance diagnostic kits and systems. Hospitals frequently maintain the cutting-edge infrastructure and technological know-how required to successfully integrate the intensity-modulated radiation therapy (IMRT) market. This guarantees the timely provision of necessary resources, and this pivotal attribute greatly advances and fortifies the Image-Guided Radiation Therapy (IGRT) industry.

A new age of treatment accuracy and specificity has been ushered in by advancements in radiation therapy technology. Radiation may be delivered extremely precisely, protecting healthy tissues and minimising side effects, thanks to techniques like proton therapy, intensity-modulated radiation treatment (IMRT), and stereotactic body radiation therapy (SBRT). Non-invasive radiation therapy does not require tissue removal or surgical incisions, in contrast to surgical therapies. As such, it leaves fewer scars and requires less time to heal, allowing patients to quickly resume their regular activities. Technological and therapeutic advances are to blame for the rise of non-invasive cancer therapies using radiation therapy. The technology used in radiation therapy has advanced dramatically over time. Radiation therapy systems, CyberKnife, and linear accelerators are examples of modern machinery that make it possible to precisely and highly target radiation therapy to malignant tumours. These methods reduce injury to surrounding healthy tissues, allowing for non-invasive therapies. Radiation therapy and real-time imaging are combined in the IGRT method. It allows medical professionals to keep an eye on the tumor's location throughout therapy, guaranteeing that radiation is precisely applied to the tumour while avoiding adjacent healthy tissues. With IGRT, repositioning patients doesn't require as many invasive treatments. The goal of non-invasive radiation therapy procedures is to reduce the number of difficulties and adverse effects that come with treating cancer. These methods enhance the patient's quality of life both during and after treatment by avoiding needless radiation exposure to healthy tissues and organs. In conclusion, improvements in technology and therapeutic approaches that enable extremely focused and accurate radiation administration are the main causes of the rise in non-invasive cancer therapies using radiation therapy. These non-invasive methods are more patient-friendly and efficient in treating a variety of cancers since they minimise side effects and lessen the need for surgery.

“Brain segment, by application, to be dominating market from 2023 to 2030.”

Major segments of the global intensity-modulated radiation market include those for the brain, gastrointestinal tract, prostate, lung, breast, and other applications. IMRT enables radiologists to perform complex operations in a non-invasive manner. Intensity-Modulated Radiation Therapy (IMRT) is a valuable tool for treating brain cancer because it can effectively navigate the intricacies of brain anatomy, minimise treatment-related uncertainty, personalise treatment plans, and work in tandem with other therapeutic techniques. This combination of attributes significantly advances and elevates IMRT's profile in the field of treating brain cancer, consequently fortifying its strategic position within the more expansive radiation therapy sector.

“North America to be largest region in Intensity-Modulated Radiotherapy Market.”

It is projected that North America will continue to hold the top spot in the intensity-modulated radiation market over the forecast period. North America, which includes both the United States and Canada, held the greatest market share for intensity-modulated radiation therapy in 2022. This is explained by the region's excellent medical technologies and strong healthcare infrastructure, which provide an atmosphere that is favourable to the adoption of cutting-edge treatment modalities like intensity-modulated radiation therapy (IMRT).

The Asia-Pacific (APAC) region's ageing population demographics highlight the significance of developing efficient cancer treatment strategies that reduce treatment-related adverse effects. This compatibility with the intensity-modulated radiation therapy market's precision-focused attributes underlines its pivotal position in enhancing the healthcare environment as a whole. The availability of cutting-edge therapies like intensity-modulated radiation therapy and the integration of bilingual patient care services inside APAC hospitals give the area a distinct attraction, particularly among a varied patient group. The region's appeal as a top healthcare destination is greatly increased by this blend of language inclusivity and state-of-the-art medical procedures. This strengthens the region's competitive position in the healthcare market and simultaneously raises the profile of IMRT.

Intensity-Modulated Radiotherapy Competitive Landscape

The competitive landscape of the Intensity-Modulated Radiotherapy Market involves assessing the competitive landscape to understand the strengths, weaknesses, opportunities, and threats of the industry. Key industry players have recognized that the adoption of Intensity-Modulated Radiotherapy technology holds the potential for further growth. The growing desire among producers to optimize their production costs has spurred collaborative efforts among companies to scale up their production capacity. This strategic collaboration not only aims to increase revenue but also seeks to establish dominance in the market.

The Intensity-Modulated Radiotherapy Market is highly competitive, with numerous companies vying for market share. Prominent companies in the Intensity-Modulated Radiotherapy Market include:

Major Players:

Varian Medical Systems (acquired by Siemens Healthineers)

Elekta AB

Accuray Incorporated

ViewRay, Inc.

Others

Recent Developments:

To lessen the burden of antimicrobial resistance, Boehringer Ingelheim, bioMérieux, and Evotec SE jointly announced in July 2022 the formation of a venture to develop actionable diagnostics and the next generation of medicines. With 80% of the entire expenditure going towards the battle against antimicrobial resistance, bioMerieux's priority within this joint venture will be on developing testing solutions for antibiotic resistance.

BioMerieux announced the acquisition deal with Specific Diagnostics in April 2022. This calculated action has improved its position in the global antimicrobial resistance diagnostics market.

BD announced in January 2022 that it has partnered with Pfizer Inc. and the international philanthropic foundation Wellcome to further research and development of diagnostics and testing solutions that would improve antimicrobial stewardship practices globally. With this joint effort, we hope to evaluate current testing methods and learn more about the benefits and drawbacks of antibiotic resistance diagnostic techniques.

MeMed announced in September 2021 that the 510(k) approval for its MeMed BV diagnostic test has been granted by the U.S. FDA. The purpose of this test is to differentiate between viral and bacterial illnesses in point-of-care settings.

Hologic, Inc. launched the fully automated Novodiag molecular diagnostic solution by Mobidiag Oy in Europe in October 2021. This system provides on-demand testing for infectious illnesses and antibiotic resistance. The Novodiag technology allows the identification of several pathogens from a single sample by combining real-time PCR and microarray capabilities.

OpGen, Inc. announced in October 2021 that the U.S. FDA has granted it 510(k) permission to launch the Acuitas AMR Gene Panel. This panel will help medical practitioners treat patients with antibiotic-resistant bacterial infections since it can test for 28 genetic antimicrobial resistance markers in a variety of pathogens.

.